Orum Therapeutics
HanGyeol Jeong has extensive experience in the research field, currently serving as a Scientist at Orum Therapeutics since August 2019. Prior to this role, HanGyeol worked as a 선임 연구원 at HANDOK from March 2014 to September 2018. Additionally, HanGyeol contributed as a Researcher at Institut Pasteur Korea from November 2011 to February 2014 and at 서울대학교병원 from February 2009 to October 2011.
This person is not in any offices
Orum Therapeutics
Orum Therapeutics is a private biotech company developing a new class of therapeutic antibodies targeting cytosolic proteins for unmet medical needs in cancer and rare diseases. Orum leverages its unique cell-penetrating antibody platform, called Oromab™ to inhibit drug targets, previously undruggable by small molecules or current antibodytherapeutics. In contrast to other approaches, Orum’s antibody platform can intracellularly deliver an active antibody therapeutic or payload, is easily adaptable to target different cell types and intracellular proteins, and does not require chemical modification.